← All Ladrx CORP filings

Ladrx CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

OTC.Pink
LADX
Ladrx CORP
8-K: LADRX Corporation Enters Liquidation, Ceases Operations
LADRX Corporation has initiated a General Assignment for the Benefit of Creditors, leading to a liquidation event and the cessation of substantially all business operations.
OTC.Pink
LADX
Ladrx CORP
8-K: LadRx Corporation Halts FDA Approval Pursuit for Aldoxorubicin Citing Resource Constraints
LadRx Corporation announced it will not pursue marketing approval for its drug aldoxorubicin under section 505(b)(2) due to insufficient resources, despite believing approval is possible.
OTC.Pink
LADX
Ladrx CORP
8-K: LadRx Corporation Announces Resignation of Director Joel Caldwell
Joel Caldwell resigned from LadRx Corporation's board of directors and all related committees, effective April 15, 2025.
OTC.Pink
LADX
Ladrx CORP
8-K: LadRx Corporation Announces Results of 2024 Annual Meeting of Stockholders
LadRx Corporation held its 2024 Annual Meeting of Stockholders on October 4, 2024, where a director was elected and other proposals were approved.
OTC.Pink
LADX
Ladrx CORP
8-K: LadRx Regains Control of Aldoxorubicin Following Termination of License Agreement with NantCell
LadRx Corporation has regained control of its aldoxorubicin drug after mutually terminating its license agreement with NantCell, and has amended its royalty agreement with XOMA.